Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
9.225 USD | -1.02% | -15.05% | -34.00% |
08/05 | Olema Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
02/04 | Goldman Sachs Initiates Olema Pharmaceuticals at Buy With $24 Price Target | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-34.00% | 52Cr | |
+25.77% | 4.5TCr | |
-0.72% | 4.26TCr | |
+46.00% | 4.18TCr | |
-5.31% | 2.9TCr | |
+9.51% | 2.61TCr | |
-21.45% | 1.9TCr | |
+6.15% | 1.28TCr | |
+27.59% | 1.21TCr | |
-3.49% | 1.18TCr |
- Stock Market
- Equities
- OLMA Stock
- News Olema Pharmaceuticals, Inc.
- Canaccord Genuity Adjusts Olema Pharmaceuticals' Price Target to $22 From $16, Maintains Buy Rating